Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
| Descriptor ID |
D009364
|
| MeSH Number(s) |
C04.697.655 C23.550.727.655
|
| Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 4 | 6 |
| 1997 | 0 | 6 | 6 |
| 1998 | 1 | 6 | 7 |
| 1999 | 1 | 0 | 1 |
| 2000 | 5 | 7 | 12 |
| 2001 | 1 | 14 | 15 |
| 2002 | 4 | 4 | 8 |
| 2003 | 4 | 8 | 12 |
| 2004 | 4 | 11 | 15 |
| 2005 | 6 | 10 | 16 |
| 2006 | 9 | 12 | 21 |
| 2007 | 12 | 7 | 19 |
| 2008 | 12 | 5 | 17 |
| 2009 | 9 | 15 | 24 |
| 2010 | 17 | 24 | 41 |
| 2011 | 9 | 18 | 27 |
| 2012 | 11 | 5 | 16 |
| 2013 | 19 | 16 | 35 |
| 2014 | 22 | 13 | 35 |
| 2015 | 21 | 17 | 38 |
| 2016 | 18 | 13 | 31 |
| 2017 | 24 | 19 | 43 |
| 2018 | 21 | 25 | 46 |
| 2019 | 20 | 22 | 42 |
| 2020 | 24 | 27 | 51 |
| 2021 | 12 | 42 | 54 |
| 2022 | 6 | 50 | 56 |
| 2023 | 2 | 45 | 47 |
| 2024 | 22 | 25 | 47 |
| 2025 | 35 | 13 | 48 |
| 2026 | 19 | 5 | 24 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma. Pediatr Blood Cancer. 2026 Nov; 73(11):e70662.
-
Inclusion of Multi-Omic Biomarkers Improves Prediction Accuracy of Response, Relapse, and Overall Survival in Acute Myeloid Leukemia Patients Receiving High-Intensity Induction Chemotherapy. Cancer Med. 2026 Sep; 15(9):e72281.
-
Variation in meningioma recurrence risk estimates across observational cohorts: the influence of calendar time, WHO classifications, geographical settings, and healthcare systems. J Neurooncol. 2026 Aug 28; 179(2).
-
Outcomes of Children With Orbital Rhabdomyosarcoma, 1991-2016: A Report From the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatr Blood Cancer. 2026 Oct; 73(10):e70613.
-
How I Approach Treatment of Relapsed Acute Lymphoblastic Leukemia in Patients With Down Syndrome. Pediatr Blood Cancer. 2026 Sep; 73(9):e70467.
-
Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials. Pediatr Blood Cancer. 2026 Sep; 73(9):e70522.
-
FcRH5?CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. Nat Med. 2026 Aug; 32(8):2909-2917.
-
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Leukemia. 2026 Oct; 40(10):2181-2190.
-
Juvenile nasopharyngeal angiofibroma: nationwide study on incidence, diagnosis, treatment, and recurrence. Rhinology. 2026 Jun 01; 64(3):405-414.
-
Local Control and Survival Outcomes in Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: The Mayo Clinic Experience. J Pediatr Hematol Oncol. 2026 Aug 01; 48(6):261-269.